Recommendations on the clinical use of bendamustine in lymphoproliferative syndromes and multiple myeloma-Reference-Cited by-同舟云学术

Recommendations on the clinical use of bendamustine in lymphoproliferative syndromes and multiple myeloma

Published:2015-08-09 Issue:5 Volume:96 Page:532-540
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:Eur J Haematol

Author:

Peñalver Francisco Javier¹,Delgado Julio²,Loscertales Javier³,Sastre Jose Luis⁴,Peña Asunción⁵,Olave María Teresa⁶,Osorio Santiago⁷,de la Fuente Adolfo⁸,Salar Antonio⁹,Grande Carlos¹⁰,Pérez Ceballos Elena¹¹,Debén Guillermo¹²,Echeveste Asunción¹³,Casado Felipe¹⁴,de la Rubia Javier¹⁵,Lahuerta Juan José¹⁰,Mateos María Victoria¹⁶

Affiliation:

1. Department of Hematology; Hospital Universitario Fundación Alcorcón; Alcorcón Madrid Spain

2. Department of Hematology; Hospital Clinic; Barcelona Spain

3. Department of Hematology; Hospital Universitario de La Princesa; Madrid Spain

4. Department of Hematology; Complexo Hospitalario de Ourense; Ourense Spain

5. Department of Hematology; Hospital Universitario San Carlos; Madrid Spain

6. Department of Hematology; Hospital Universitario Lozano Blesa; Zaragoza Spain

7. Department of Hematology; Hospital Universitario Gregorio Marañón; Madrid Spain

8. Department of Hematology; MD Anderson Cancer Center; Madrid Spain

9. Department of Hematology; Hospital del Mar; Barcelona Spain

10. Department of Hematology; Hospital Universitario 12 de Octubre; Madrid Spain

11. Department of Hematology; Hospital Universitario Morales Messeguer; Murcia Spain

12. Department of Hematology; Complexo Hospitalario de La Coruña; La Coruña Spain

13. Department of Hematology; Hospital Universitario Donostia; San Sebastián Spain

14. Department of Hematology; Hospital Virgen de la Salud; Toledo Spain

15. Department of Hematology; Hospital Universitario Doctor Peset; Valencia Spain

16. Department of Hematology; IBSAL-Hospital Universitario de Salamanca; Salamanca Spain

Publisher

Wiley

Subject

Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ejh.12633/fullpdf

Reference50 articles.

1. Bendamustine is effective therapy in patients with Rituximab-Refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter study;Kahl;Cancer,2010

2. Mechanism of action: the unique pattern of bendamustine-induced cytotoxicity;Leoni;Semin Hematol,2011

3. Astellas Pharma GmbH Levact (Bendamustine hydrochloride, 2.5 mg/ml). Powder for concentrate for solution for infusion 2010 www.ema.europe.eu/ema/

4. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study;Friedberg;J Clin Oncol,2008

5. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia;Knauf;J Clin Oncol,2009

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience;Blood Advances;2023-11-15

2. Response‐adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first‐line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial;Cancer Medicine;2019-10